Drug combo aims to boost remission in rare lymphoma

NCT ID NCT04416451

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial investigates whether combining rituximab (an antibody therapy) with venetoclax (a targeted pill) can effectively treat marginal zone lymphoma in people who have not yet received any treatment for their cancer. The study enrolls adults with measurable disease and tracks how many achieve a complete response. The goal is to see if this drug pair can become a new standard first-line option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and venetoclax
What this could lead to: If effective, this combination could offer a new first-line treatment option for marginal zone lymphoma, potentially improving how many patients achieve complete remission.
What could go wrong: This is a small, early-phase study (only 6 participants) with no control group, so results may not be generalizable. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Show contact details

Locations

City of Hope Cancer Center (Data collection only)

Duarte, California, 91010, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Rockville Centre (All Protocol Activities)

Rockville Centre, New York, 11570, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.